 Our study found that Resancuzumab was effective and safe for psoriasis management in a real-life setting over a period of two years. We observed a statistically significant reduction in psoriasis severity scores from week 16 and this effect was sustained until week 104. No serious adverse events were recorded during this study. Further research is needed to confirm these findings and to expand the available data to help establish the best evidence-based biologic selection algorithm. This article was authored by Mateo Magna, Angelo Regiero, Teresa Batista, and others.